Constipation drugs may reveal new clues about gut health in Barrett's esophagus patients

NCT ID NCT05107219

First seen Oct 31, 2025 · Last updated May 06, 2026 · Updated 27 times

Summary

This early study looked at whether two FDA-approved constipation drugs, plecanatide and linaclotide, change levels of a chemical called cGMP in the small intestine. Researchers compared tissue samples from 43 adults with Barrett esophagus or GERD who took one of the drugs or no drug. The goal was to understand how these drugs work in the gut, not to treat the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for BARRETT ESOPHAGUS are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • Fox Chase Cancer Center

    Philadelphia, Pennsylvania, 19111, United States

  • Mayo Clinic in Arizona

    Scottsdale, Arizona, 85259, United States

  • Thomas Jefferson University Hospital

    Philadelphia, Pennsylvania, 19107, United States

  • University of Wisconsin Carbone Cancer Center - University Hospital

    Madison, Wisconsin, 53792, United States

Conditions

Explore the condition pages connected to this study.